Mostrar el registro sencillo del ítem

dc.contributor.authorMartin-Galiano, Antonio Javier 
dc.contributor.authorDíez-Fuertes, Francisco 
dc.contributor.authorMcConnell, Michael J 
dc.contributor.authorLopez, Daniel 
dc.date.accessioned2022-05-09T13:00:50Z
dc.date.available2022-05-09T13:00:50Z
dc.date.issued2021-11
dc.identifier.citationFront Immunol. 2021 Nov 25;12:732693.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14350
dc.description.abstractThe effect of emerging SARS-CoV-2 variants on vaccine efficacy is of critical importance. In this study, the potential impact of mutations that facilitate escape from the cytotoxic cellular immune response in these new virus variants for the 551 most abundant HLA class I alleles was analyzed. Computational prediction showed that most of these alleles, that cover >90% of the population, contain enough epitopes without escape mutations in the principal SARS-CoV-2 variants. These data suggest that the cytotoxic cellular immune protection elicited by vaccination is not greatly affected by emerging SARS-CoV-2 variants.es_ES
dc.description.sponsorshipThis research was supported by grants from COV20_00679 (MPY 222-20), to MM, MPY 509/19 to AM-G, and MPY 388/18 to DL of “Acción Estratégica en Salud” from the ISCIII.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHLAes_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectT cell epitopees_ES
dc.subjectEpidemices_ES
dc.subjectEscape mutantes_ES
dc.subjectVaccinees_ES
dc.titlePredicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concernes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID34899692es_ES
dc.format.volume12es_ES
dc.format.page732693es_ES
dc.identifier.doi10.3389/fimmu.2021.732693es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1664-3224es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2021.732693es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/MPY222/20es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/MPY388/18es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/MPY509/19es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/COV20_00679es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional